Login / Signup

Safety, Tolerability, and Pharmacokinetics of Senaparib, a Novel PARP1/2 Inhibitor, in Chinese Patients With Advanced Solid Tumors: A Phase I Trial.

Junning CaoHongqian GuoDongmei JiWeina ShenShun ZhangChih-Yi HsiehSui Xiong CaiYe Edward TianCong XuPin ZhangBinghe Xu
Published in: The oncologist (2023)
NCT03508011.
Keyphrases
  • open label
  • phase iii
  • phase ii
  • study protocol
  • dna damage
  • clinical trial
  • dna repair
  • placebo controlled
  • double blind